Three months of combination therapy with nano‐curcumin reduces the inflammation and lipoprotein (a) in type 2 diabetic patients with mild to moderate coronary artery disease: Evidence of a randomized, double‐blinded, placebo‐controlled clinical trial

Mostafa Dastani,Hamid Reza Rahimi,Vahid Reza Askari,Mahmoud Reza Jaafari,Lida Jarahi,Asal Yadollahi,Vafa Baradaran Rahimi
DOI: https://doi.org/10.1002/biof.1874
2022-06-09
BioFactors
Abstract:Diabetes is one of the most common chronic diseases worldwide. Systemic inflammation (high‐sensitivity C‐reactive protein (hs‐CRP)) and lipid metabolism disruption (lipoprotein A, LipoPr (a)) play a critical role in developing and progressing atherosclerosis and acute coronary syndrome in diabetic patients. The anti‐oxidant and anti‐inflammatory effects of curcumin have been emphasized previously. Therefore, we aimed to evaluate the impact of nano‐curcumin on cardiovascular risk factors in type 2 diabetic patients with mild to moderate coronary artery disease (CAD). We performed a randomized, double‐blinded, placebo‐controlled clinical trial with type 2 diabetic patients (n = 64), and mild to moderate CAD (<70% stenosis in angiography). The patients received nano‐curcumin (80 mg/day) or placebo along with optimal medications for 90 days. The biofactors, including hs‐CRP and LipoPr (a), and lipid profile, were measured at the admission of patients and end of the study. Nano‐curcumin significantly mitigated the hs‐CRP and LipoPr (a) levels following 90 days of treatment (P
biochemistry & molecular biology,endocrinology & metabolism
What problem does this paper attempt to address?